AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2012-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT01598571
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Advanced Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99
- Registration Number
- NCT01597388
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment
Phase 1
Terminated
- Conditions
- Breast Neoplasm
- Interventions
- Drug: Drug-AZD8931Drug: Drug-Placebo
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3
- Registration Number
- NCT01596530
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Bioequivalence Study Comparing D961H Sachet and D961H Capsule in Japanese Healthy Male Subjects
Phase 1
Completed
- Conditions
- Bioequivalence Study
- Interventions
- Drug: D961H HPMC capsule 20 mgDrug: D961H Sachet 20 mg
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 71
- Registration Number
- NCT01595425
- Locations
- 🇯🇵
Research Unit, Fukuoka-shi, Fukuoka, Japan
Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT01594619
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
European Drug Utilization Study
Completed
- Conditions
- Major Depressive Disorder (MDD)
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 814
- Registration Number
- NCT01594996
- Locations
- 🇩🇪
Research Site, Dortmund, Germany
Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT01588626
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 43
- Registration Number
- NCT01588548
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
AZD8683 Multiple Dose Study in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT01584739
Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer
Phase 2
Terminated
- Conditions
- Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
- Interventions
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT01579578
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan